CA
NZ
UK
AU
IND
US
…
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Cibus Global LLC (NASDAQ: CBUS) are limited, preventing a clear, independently verifiable description of its core business from available public sources. Long-term growth may depend on successful execution of its stated business plan, access to capital, and favorable market or regulatory conditions; investors may find appeal in potential upside if management executes and market demand materializes.
Material risks include limited public disclosure and low liquidity, execution and financing risk, and potential regulatory or market-acceptance challenges; investors should monitor SEC filings, management updates, and trading volume.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -132.17M | -282.68M | -337.64M | -16.89M | -29.20M |
| Minority interest | 5.12M | 31.32M | 70.01M | - | - |
| Net income | -127.08M | -251.39M | -267.63M | -16.89M | -29.20M |
| Selling general administrative | 26.91M | 30.80M | 23.14M | 10.97M | 15.38M |
| Gross profit | -2.28M | 4.26M | 1.42M | 0.16M | -2.57M |
| Reconciled depreciation | 5.92M | 6.86M | 3.25M | 1.53M | 2.34M |
| Ebit | -67.46M | -248.49M | -319.28M | -23.90M | -30.86M |
| Ebitda | -61.54M | -241.63M | -314.58M | -22.37M | -28.52M |
| Depreciation and amortization | 5.92M | 6.86M | 4.69M | 1.53M | 2.34M |
| Operating income | -67.46M | -258.40M | -318.88M | -22.37M | -29.33M |
| Other operating expenses | 71.10M | 262.66M | 320.70M | 22.53M | 55.32M |
| Interest expense | 35.48M | 34.19M | 18.89M | 0.07M | 1.43M |
| Tax provision | 0.03M | 0.03M | -0.00M | 0.00M | 0.00M |
| Interest income | 0.44M | 0.63M | 0.53M | 0.06M | 0.02M |
| Net interest income | -35.04M | -33.56M | -10.40M | -0.09M | -1.41M |
| Income tax expense | 0.03M | 0.03M | -0.00M | -1.45M | -0.11M |
| Total revenue | 3.64M | 4.26M | 1.82M | 0.16M | 25.99M |
| Total operating expenses | 65.18M | 262.66M | 320.31M | 22.53M | 26.76M |
| Cost of revenue | 5.92M | 6.86M | 0.40M | 0.00M | 28.56M |
| Total other income expense net | -64.71M | -24.29M | -18.76M | 5.57M | 1.55M |
| Net income from continuing ops | -132.20M | -282.71M | -63.27M | -16.89M | -29.20M |
| Net income applicable to common shares | - | - | - | -16.89M | -29.20M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 305.05M | 350.07M | 544.41M | 22.42M | 37.19M |
| Intangible assets | 31.68M | 33.58M | 35.41M | - | - |
| Other current assets | 1.44M | 1.47M | 1.99M | 0.61M | 0.86M |
| Total liab | 283.22M | 252.24M | 206.12M | 15.19M | 23.06M |
| Total stockholder equity | 21.83M | 97.83M | 293.47M | 7.23M | 14.13M |
| Other current liab | 5.09M | 8.15M | 7.04M | 1.23M | 3.22M |
| Common stock | 0.08M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -858.25M | -731.17M | -479.78M | -212.15M | -196.09M |
| Other liab | - | - | - | 0.08M | 0.70M |
| Good will | 232.52M | 253.47M | 434.90M | - | - |
| Other assets | - | - | - | 0.16M | 0.28M |
| Cash | 9.92M | 14.43M | 32.70M | 3.43M | 13.82M |
| Total current liabilities | 16.86M | 19.88M | 21.32M | 1.66M | 4.85M |
| Current deferred revenue | 0.54M | 0.93M | 1.21M | 0.46M | 3.03M |
| Net debt | 258.04M | 21.85M | -8.08M | 10.12M | 4.05M |
| Short term debt | 3.17M | 0.44M | 6.95M | 0.10M | 0.37M |
| Short long term debt | 0.43M | 0.44M | 0.83M | - | - |
| Short long term debt total | 267.96M | 36.29M | 24.62M | 13.54M | 17.88M |
| Other stockholder equity | 880.03M | 823.30M | 771.82M | 219.38M | 210.22M |
| Property plant equipment | - | - | - | 18.13M | 21.73M |
| Total current assets | 12.07M | 16.95M | 35.22M | 4.13M | 15.18M |
| Net tangible assets | - | - | - | 7.23M | 14.13M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 0.70M | 1.04M | 0.53M | - | 0.00M |
| Long term debt | 0.09M | 0.23M | 0.54M | - | - |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 8.07M | 5.96M | 6.13M | 0.34M | 1.26M |
| Accumulated other comprehensive income | 0.04M | 0.01M | 0.01M | - | - |
| Non currrent assets other | 0.93M | 1.39M | 1.42M | 0.16M | 0.28M |
| Non current assets total | 292.98M | 333.12M | 509.19M | 18.29M | 22.01M |
| Capital lease obligations | 32.51M | 35.62M | 23.25M | 13.54M | 17.88M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.81M | 55.50M | -1.52M | 11.20M |
| Change to liabilities | - | - | - | -0.23M | -0.36M |
| Total cashflows from investing activities | -0.58M | -0.81M | 55.06M | -1.52M | 11.20M |
| Net borrowings | -1.11M | -0.88M | 2.31M | -0.38M | -0.36M |
| Total cash from financing activities | 46.65M | 40.60M | 20.32M | 9.99M | 3.74M |
| Change to operating activities | - | - | - | -2.66M | 1.58M |
| Net income | -127.08M | -282.71M | -267.63M | -16.89M | -29.20M |
| Change in cash | -4.51M | -18.27M | 29.17M | -10.89M | -3.87M |
| Begin period cash flow | 14.43M | 32.70M | 3.53M | 14.42M | 18.29M |
| End period cash flow | 9.92M | 14.43M | 32.70M | 3.53M | 14.42M |
| Total cash from operating activities | -50.59M | -58.04M | -46.21M | -19.36M | -18.81M |
| Issuance of capital stock | 50.10M | 43.90M | 0.33M | 11.54M | 4.38M |
| Depreciation | 5.92M | 6.86M | 4.69M | 1.53M | 2.34M |
| Change to inventory | - | - | -0.92M | 0.00M | 1.38M |
| Change to account receivables | 0.54M | -0.51M | 1.70M | 0.00M | 4.89M |
| Other cashflows from financing activities | -0.14M | -2.42M | 1.76M | -1.17M | -0.27M |
| Change to netincome | - | - | - | -1.12M | 0.56M |
| Capital expenditures | 0.58M | 0.81M | 4.32M | 1.52M | 0.50M |
| Change in working capital | 2.32M | 0.38M | 0.96M | -2.88M | 7.49M |
| Stock based compensation | 8.19M | 10.75M | 16.09M | 4.00M | 2.09M |
| Other non cash items | 60.06M | 206.68M | 215.76M | -5.12M | -1.53M |
| Free cash flow | -51.17M | -58.85M | -50.53M | -20.88M | -19.31M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CBUS Cibus Global LLC |
-0.01 0.43% |
1.15 | - | - | 33.14 | 5.46 | 39.11 | -1.15 |
| NVO Novo Nordisk A/S |
-0.68 1.64% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.02 0.55% |
547.85 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
916.06 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Rory Balfour Riggs M.B.A. | Co-Founder, CEO & Chairman | 1953 |
| Dr. Peter Beetham B.Sc., Ph.D. | Co-Founder, President, COO & Director | 1963 |
| Dr. Greg Gocal Ph.D. | Co-Founder, Chief Scientific Officer & Executive VP | 1969 |
| Dr. Wade Hampton King | Chief Financial Officer | 1958 |
| Mr. Jason Stokes J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | NA |
| Ms. Rosa Cheuk Kim J.D. | Senior Vice President of Legal | NA |
| Dr. James Radtke Ph.D. | Senior Vice President of Product Development | NA |
| Mr. Tony Moran | Senior Vice President of International Development | NA |
| Norm Sissons | Senior Vice President of Seed & Traits | NA |
| Ms. Noel Sauer Ph.D. | Senior Vice President of Research | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...